Role of pramipexole in key research areas of Parkinson’s disease management discussed at 12th EFNS Congress

PROUD is the first study to combine early versus delayed pramipexole treatment with a parallel imaging arm to investigate potential clinical benefits of early treatment of patients with Parkinson’s disease

MADRID, Spain, 25 August 2008 – Data presented during the 12th Congress of the European Federation of Neurological Sciences (EFNS), held in Madrid, Spain, from 23 to 26 August, highlight important new ongoing studies with pramipexole in a number of key research areas in Parkinson’s disease (PD): clinical benefits of early treatment initiation, management of PD-related depressive symptoms and a new formulation currently under investigation.

Professor Anthony Schapira, Chairman of the University Department of Clinical Neurosciences, Institute of Neurology, Queen Square, UCL, and Professor of Neurology at the National Hospital and Royal Free Hospital, London, UK and lead study investigator for PROUD*,1, presented a new approach to investigate the slowing of clinical progression in PD, a key focus of current research due to this important unmet need. Previous pramipexole studies have suggested a potential neuroprotective effect, such as the CALM-PD** study2,3 and in vitro studies. PROUD, however, is the first study to combine measurements of clinical outcomes in a PD patient with measurements of dopamine transporter density of certain brain areas (basal ganglia), through a SPECT imaging arm of the study.1

Commenting on the study so far, Professor Schapira said: “The debate on when and how to treat early Parkinson’s disease patients has been ongoing. Currently, treatment would typically be initiated when symptoms have caused disability. However, providing the medical evidence for a treatment to retard or prevent the progression of PD is a major therapeutic priority and the PROUD study aims to shed more light into this question. Pramipexole was considered an optimal candidate for this study due to evidence suggesting possible benefits to PD patients beyond treating the well-known core symptoms. Based on the unique technique used in this study, PROUD may provide a major breakthrough in our understanding of early PD treatment which would offer hope to the ever increasing number of patients diagnosed with Parkinson’s disease.”

Study results are expected to be available in 2009.

Pramipexole studies pursuing other new avenues of research to meet treatment needs
Further areas of current PD research with pramipexole are the management of PD-related depressive symptoms and ongoing studies to evaluate a new formulation so as to provide physicians and patients using pramipexole with an even broader treatment regimen to better meet differing patient needs and lifestyles.4,5,6

PD-related depressive symptoms
A new pramipexole study conducted in approximately 70 European centres aims to assess management of depressive symptoms in PD patients.7 Emerging data suggest that pramipexole may have a positive effect on depressive symptoms and motivation associated with PD, in addition to effectively controlling the motor symptoms of PD.8-16 The specific receptor profile of pramipexole may be responsible for the possible antidepressant properties of this compound and clinical research is ongoing to determine this aspect of pramipexole’s pharmacological profile in more detail.17,18,19

Professor Paolo Barone, Department of Neurological Sciences, University of Napoli-Federico II, Naples, Italy and lead investigator of both PRODEST4 and the new European study7 said: “Previously, the PRODEST study identified that PD-related depressive symptoms are common, with nearly half of those PD patients receiving anti-depressants continuing to experience depressive symptoms. These symptoms impact significantly on quality of life, both for PD patients and their carers. The new European study aims to provide answers on the role pramipexole may play in managing these commonly experienced PD-related depressive symptoms that are often under-recognised and consequently under-treated.”

Widening choice of pramipexole treatment options
Favourable results of pharmacokinetic phase I studies with a new once daily pramipexole extended release formulation were presented at EFNS and support the development of this new formulation.5,6 Pramipexole is the leading dopamine agonist treatment for PD and these ongoing studies aim to add to the existing treatment regimen with a once daily formulation to go one step further to meeting a broader range of patients’ needs.

Please be advised
This release is provided by Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This information is not intended for distribution within the U.S.A.

Notes to Editor:
About Parkinson’s disease (PD)
PD is the second most common chronic neurological disorder in older adults after Alzheimer`s. Its worldwide prevalence is estimated to be approximately one to two percent of those over 65 years.20,21 Although traditionally PD is associated with motor symptoms (such as tremor, rigidity, slowed motion, imbalance, shuffling gait, loss of facial expression), the non-motor symptoms, including depressive symptoms, pain, cognitive impairment and sleep disorders can be significant. The symptoms can vary from patient to patient, but worsen over time.

About PROUD1 (*Assessment of Potential ImPact of PRamipexole On Underlying Disease)
The PROUD study was designed to test the hypothesis that early administration of pramipexole can modify Parkinson’s disease and delay the progression of motor function deterioration in early PD patients. The PROUD study is unique in its design by including a parallel SPECT imaging arm to measure the level of neuron degeneration in the brain.

534 patients with early PD in 98 centres in ten countries were randomised to receive either 1.5mg/day pramipexole or placebo. After six to nine months all patients were given pramipexole for the remainder of the 15 months. The primary endpoint of the study is the change in UPDRS part I, II and III at 15 months compared to baseline values by a blinded rater. UPDRS part I, II and III relate to mentation, behaviour and mood (I), activities of daily living (II) and motor symptoms (III). Secondary endpoints include the change in motor, cognitive and quality of life indices and striatal dopamine transporter (DAT) density by [123I] FP-CIT SPECT in 158 patients between baseline and 15 months.

**About CALM-PD
In the earlier performed CALM-PD trial, 301 patients were randomised to double-blind therapy with pramipexole or levodopa; adjuvant therapy was allowed as rescue if necessary. After four years, initial treatment with pramipexole reduced the risk of developing dyskinesias (involuntary jerking movements, themselves very disabling) by more than 50% versus initial treatment with levodopa.22 These results played a pivotal role in recent guidelines by the American Academy of Neurology which support the advantages of starting treatment with a dopamine agonist.23 While the CALM-PD trial compared the pooled analysis (both mono and combination therapy) after two and four years, this new analysis assessed the effects of mono vs. combination therapy separately in terms of the dyskinesia rate.

About pramipexole
Pramipexole (known under the trade names Mirapexin®, Sifrol®, Mirapex® and Pexola®) is a compound from Boehringer Ingelheim research first approved in 1997 for the treatment of the signs and symptoms of idiopathic Parkinson`s disease, as monotherapy or in combination with levodopa. Pramipexole was approved in 2006 for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS). Pramipexole is currently marketed in over 70 countries across the globe.

The most commonly reported adverse reactions in early and late Parkinson’s disease in clinical trials were dizziness, nausea, dyskinesia, hypotension, somnolence, insomnia, hallucination, constipation, headache and fatigue. The most commonly reported adverse reactions in clinical trials for Restless Legs Syndrome were nausea, headache, fatigue and dizziness.

Pramipexole may cause patients to fall asleep without any warning, even while doing normal daily activities such as driving. When taking pramipexole hallucinations may occur and sometimes patients may feel dizzy, sweaty or nauseated upon standing up. It should be noted that impulse control disorders/compulsive behaviours may occur while taking medicines to treat Parkinson`s disease, including pramipexole.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

References:
1 Schapira A et al. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson’s disease. Poster P1366 presented at the 12th Congress of the European Federation of Neurological Sciences, Madrid, Spain, 24 August 2008
2 Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson’s disease progression. JAMA 2002; 287(13): 1653-1661
3 Jennings DL et al. InSPECT: Investigating the effect of short-term treatment with pramipexole or levodopa on [123I] and SPECT imaging. Abstract 465 at 11th International Congress of Parkinson’s Disease and Movement Disorders, Istanbul 2007
4 Barone P et al. PRODEST – Depressive symptoms in Parkinson’s disease: Pattern across scales. Poster Presentation P-01 / 1.167. 10 December 2007 XVIIth WFN World Congress of Parkinson’s Disease and Related Disorders
5 Koenen-Bergmann, M et al. A multiple rising-dose bioequivalence Phase I study with pramipexole extended release (ER). Poster P1248 presented at the 12th Congress of the European Federation of Neurological Sciences, Madrid, Spain, 24 August 2008
6 Haertter, S et al. A single dose five-way cross-over study to establish an in vitro/in vivo correlation (IVIVC) for oral extended release (ER) formulations with 0.375 mg pramipexole. Poster P1244 presented at the 12th Congress of the European Federation of Neurological Sciences, Madrid, Spain, 24 August 2008
7 Barone P et al. Design of a randomized, placebo-controlled trial of pramipexole in patients with Parkinson’s disease and depressive symptoms (study 248.596) Poster 601 presented at Movement Disorders Society’s 12th International Congress of Parkinson’s Disease and Movement Disorders, June 2008, Chicago, USA
8 Möller JC et al. Long-term efficacy and safety of pramipexole in advanced Parkinson`s disease: results from a European multicenter trial. Mov Disord 2005 May; 20(5): 602-10
9 Rektorova I et al. Pramipexole and pergolide in the treatment of depression in Parkinson`s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399-406
10 Reichmann H et al. Pramipexole in routine clinical practice. CNS Drugs 2003; 17(13): 965-973
11 Lemke MR et al. Depression and Parkinson’s disease. J Neurol 2004 Sep;251 Suppl 6:VI/24-7.
12 Lemke MR et al. Anhedonia, depression, and motor functioning in Parkinson`s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005 Spring; 17(2): 214-20.
13 Rektorova I et al. Cognitive performance in people with Parkinson`s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12: 9-15.
14 Goldberg JF et al. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004 Mar; 161(3): 564-6.
15 Künig G et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin Neuropharm 1999; 22: 301-305.
16 Barone P et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601-7.
17 Houben J et al. Pramipexole improves depressive and motivational symptoms in Parkinson’s disease. Abstract no. P575, presented at MDS 2006; Kyoto, Japan.
18 Barone P et al. Depressive symptoms in Parkinson’s disease: Design and methods of an observational study. Mov Disord. Vol. 21, Suppl. 15, 2006: S476.
19 Barone P et al. Depression and antidepressant use in Parkinson’s disease: Results from the PRODEST-PD study. Abstract P1122 poster presented at 11th Congress of EFNS, Brussels, 26 Aug 2007.
20 Zhang ZX, et al. Worldwide occurrence of Parkinson`s disease: An updated review. Neuroepidemiology. 1993;12:195-208.
21 de Rijk MC et al. Prevalence of Parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:10-5.
22 Parkinson Study Group, Holloway RG et al. Pramipexole vs levodopa as initial treatment for Parkinson disease. Arch Neurol 2004; 61(7): 1044-1053.
23 Miyasaki JM et al. Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review. Neurology 2002; 58; 11-17.


Related links: Information Pack on Parkinson`s Disease


Media contact
Boehringer Ingelheim GmbH
Corporate Division Communications
Ursula Bardon
Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY
 

Posted: August 2008

View comments

Hide
(web2)